By Sai Siramdas, Chief Technology Officer, Flora Health

Executive Summary

• EHR environments cannot and should not be measured using web-based tracking models.

• Upstream clinical signals reveal intent before a claim or prescription is written.

• Flora Health's integrator approach enables precise, non-invasive validation and targeting.

• A new class of clinical-signal intelligence solutions will reshape pharma marketing and access in 2026.

Building on Angelo's 2026 Vision

Our CEO, Angelo Campano, opened this year's Flora Health Insider Perspectives series by emphasizing deeper collaboration across pharma, health systems, EHR partners, and technology teams. That foundation sets the stage for a shift we've anticipated for years: healthcare is finally moving upstream, toward understanding what happens before treatment decisions are made. Downstream metrics like claims or clicks tell only part of the story — the most meaningful clinical signals occur earlier, during the diagnostic process and inside workflow moments.

Why EHR Measurement Is Fundamentally Different

EHR is not the web, and it cannot be measured like the web. EHR environments operate under a different set of rules: no third-party cookies, no behavioral tracking or browsing history, no cross-site attribution, no non-human traffic, and no ability to store or transfer patient-level data — data exists momentarily in a secure, one-directional connection and is then dropped. Imposing Google-style tracking into clinical systems isn't just technically incompatible; it conflicts with how healthcare data is designed to function.

Why Healthcare Must Move Upstream

Traditional healthcare media relies on downstream data like claims and prescriptions, which appear after the major clinical decisions are already made. The real opportunity lives upstream — in lab orders, diagnostic patterns, symptom combinations, workflow actions, and real-time clinical context. Upstream intelligence helps teams understand intent, not just outcomes, engaging clinicians while decisions are still forming.

Why This Shift Is Happening Now

Several forces are converging: privacy regulations continue to tighten, health systems are modernizing EHR infrastructure and demanding workflow-safe technology, pharma teams face growing pressure to demonstrate relevance earlier in the care journey, and AI has matured enough to interpret patterns without retaining sensitive information. Together, these changes make legacy downstream measurement models less effective — and upstream intelligence not just possible, but necessary. In 2026, upstream intelligence moves from advantage to requirement.

What Pharma Teams Commonly Misunderstand

EHR partners do not access or retain patient data. Behavioral web tracking is not allowed. Basic impression and click metrics translate to clinical environments; behavioral metrics do not. Measurement inside clinical systems must be accurate but never intrusive — validated using external, compliant data sources, enabling context-aware targeting without disrupting clinical workflow.

Why Flora Health Is Positioned to Lead

Our team has shaped EHR media from its earliest days, partnering deeply with health systems, data providers, and workflow technology teams to build solutions purpose-built for clinical environments. In 2026, Flora Health is accelerating its platform to illuminate clinical intent earlier, validate delivery, generate data-driven audiences, and connect intelligence directly to activation platforms — conceptually similar to audience-generation platforms, but uniquely designed for healthcare's regulatory and clinical requirements.

Five Things Leaders Should Keep in Mind in 2026

EHR is not the web — stop forcing digital advertising models into clinical systems.

Upstream signals will outperform downstream metrics.

Compliance determines what is possible.

Validation can be precise without tracking behavior.

Clinical-signal intelligence is becoming foundational to media planning, measurement, and optimization.

The future is interoperability, workflow intelligence, and real-time clinical context. Flora Health's role is clear: we build technology that fits the clinical ecosystem — not the other way around. The shift upstream is already underway. In 2026, it becomes measurable, actionable, and scalable.